petPhealthcare firm Swedencare's Q4 prelim revenue grows 11% organically

Swedencare AB (publ)

30/01/2026 07:39

Corrects typographical error in headline

Overview

Sweden pet healthcare firm's Q4 prelim revenue grew 11% organically to 682 MSEK

Profitability impacted by higher marketing costs and operational disruptions

Company to complete Amazon transition for NaturVet

Outlook

Swedencare plans to complete Amazon transition for NaturVet in 2026

Company aims to expand veterinary collaborations in Europe and North America

Swedencare expects to normalize margins within Big Box channel

Result Drivers

HIGHER MARKETING COSTS - Profitability affected by increased marketing expenses for Amazon and Big Box channel initiatives

OPERATIONAL DISRUPTIONS - ERP implementation at NaturVet led to reduced execution speed and delayed shipments

BIG BOX CHANNEL INVESTMENTS - Elevated marketing investments to build awareness and support rebranding in Big Box channel

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
SEK 682 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Swedencare AB (publ) is SEK49.00, about 44.3% above its January 29 closing price of SEK33.95

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: ID:nMFN7YSB6K

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)